National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 9) (PB 104 of 2018) (Cth)

PB 104 of 2018

National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 9)

National Health Act 1953

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated    28 November 2018

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 9).

(2)   This Determination may also be cited as PB 104 of 2018.

1. Commencement

This Determination commences on 1 December 2018.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Bendamustine

Insert

Benralizumab

[2]     Schedule 1, after item dealing with Erlotinib

Insert

Ertugliflozin

[3]     Schedule 1, after item dealing with Midazolam

Insert

Midostaurin

[4]     Schedule 1, after item dealing with Tipranavir

Omit

Tocilizumab

[5]     Schedule 1, after item dealing with Travoprost

Insert

Trifluridine with tipiracil

[6]     Schedule 2, after item dealing with Tobramycin

Insert

Tocilizumab